Toxicology studies of biotinylated anti-CD46 mixed with Streptavidin-ZAP were performed in non-human primates that showed the potential of CD46 for use as a target in adenocarcinoma and neuroendocrine types of metastatic castration-resistant prostate cancer (mCRPC) [61]. This evidence concerns the gene CD46 and adenocarcinoma.